Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
The Pharma Data
SEPTEMBER 11, 2021
This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development. About Twist Bioscience Corporation.
Let's personalize your content